{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "regularMarketChangePercent": 0.52083284, "regularMarketPrice": 3.86, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.46, "epsForward": -0.63, "epsCurrentYear": -0.7, "priceEpsCurrentYear": -5.5142856, "sharesOutstanding": 46584500, "bookValue": 1.292, "fiftyDayAverage": 4.3918, "fiftyDayAverageChange": -0.53180003, "fiftyDayAverageChangePercent": -0.12108931, "twoHundredDayAverage": 5.0327, "twoHundredDayAverageChange": -1.1727002, "twoHundredDayAverageChangePercent": -0.2330161, "marketCap": 183035024, "forwardPE": -6.126984, "priceToBook": 2.9876158, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "exchange": "FRA", "shortName": "HEIDELBERG PHARMA AG O.N.", "longName": "Heidelberg Pharma AG", "messageBoardId": "finmb_131424", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "firstTradeDateMilliseconds": 1163401200000, "priceHint": 4, "regularMarketChange": 0.01999998, "regularMarketTime": 1683871653, "regularMarketDayHigh": 3.86, "regularMarketDayRange": "3.86 - 3.86", "regularMarketDayLow": 3.86, "regularMarketVolume": 200, "regularMarketPreviousClose": 3.84, "bid": 3.92, "ask": 4.02, "fullExchangeName": "Frankfurt", "financialCurrency": "EUR", "regularMarketOpen": 3.86, "averageDailyVolume3Month": 470, "averageDailyVolume10Day": 1109, "fiftyTwoWeekLowChange": 0.01999998, "fiftyTwoWeekLowChangePercent": 0.0052083284, "fiftyTwoWeekRange": "3.84 - 6.46", "fiftyTwoWeekHighChange": -2.6000001, "fiftyTwoWeekHighChangePercent": -0.4024768, "fiftyTwoWeekLow": 3.84, "fiftyTwoWeekHigh": 6.46, "earningsTimestamp": 1689228000, "earningsTimestampStart": 1689228000, "earningsTimestampEnd": 1689228000, "trailingAnnualDividendRate": 0.0, "symbol": "HPHA.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Gregor-Mendel-Strasse 22", "city": "Ladenburg", "zip": "68526", "country": "Germany", "phone": "49 6203 1009 0", "fax": "49 6203 1009 19", "website": "https://heidelberg-pharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-XX for the treatment of solid/hematological tumors; MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; and TAK-ATACs for oncology. It is also developing TLX250-CDx, a diagnostic antibody for diagnosing renal cancer that is in Phase III trials; urothelial carcinoma or bladder cancer, which is in Phase II study; and triple-negative breast cancer that is in Phase II study. In addition, the company develops TLX250 (girentuximab), a diagnostic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II/III study to treat COVID-19, as well as for the treatment of advanced cholangiocarcinoma; and LH011 for pancreatic cancer. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.", "fullTimeEmployees": 100, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jan  Schmidt-Brand", "age": 64, "title": "CEO, CFO & Member of the Exec. Management Board", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": {"raw": 388895, "fmt": "388.89k", "longFmt": "388,895"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Prof. Andreas  Pahl", "title": "Chief Scientific Officer & Member of the Exec. Management Board", "fiscalYear": 2022, "totalPay": {"raw": 328276, "fmt": "328.28k", "longFmt": "328,276"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jorg  Kemkowski", "title": "Chief Operating Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Sylvia  Wimmer", "title": "Sr. Mang. of Corp. Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Andras  Strassz", "title": "Chief Medical Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mathias  Locher", "title": "Chief Devel. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. George Octavian Badescu", "title": "Chief Bus. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}